Big drugmakers are shifting more licensing-deal value to future milestones, with upfront cash representing a smaller share, per a JPMorgan-DealForma report reviewed exclusively by Axios Pro.
Why it matters: Biotechs must meet specified milestones before collecting much of a licensing deal's potential value, delaying access to capital.
